DK0659082T3 - Anvendelse af cytochrom P450 inhibitorer til inhibering af metabolismen af nitrogensubstituerede acridiner - Google Patents

Anvendelse af cytochrom P450 inhibitorer til inhibering af metabolismen af nitrogensubstituerede acridiner

Info

Publication number
DK0659082T3
DK0659082T3 DK93923110T DK93923110T DK0659082T3 DK 0659082 T3 DK0659082 T3 DK 0659082T3 DK 93923110 T DK93923110 T DK 93923110T DK 93923110 T DK93923110 T DK 93923110T DK 0659082 T3 DK0659082 T3 DK 0659082T3
Authority
DK
Denmark
Prior art keywords
cytochrome
metabolism
inhibitors
inhibit
nitrogen
Prior art date
Application number
DK93923110T
Other languages
English (en)
Inventor
Thomas F Woolf
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/943,323 external-priority patent/US5422350A/en
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of DK0659082T3 publication Critical patent/DK0659082T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Lubricants (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
DK93923110T 1992-09-10 1993-09-08 Anvendelse af cytochrom P450 inhibitorer til inhibering af metabolismen af nitrogensubstituerede acridiner DK0659082T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/943,323 US5422350A (en) 1992-09-10 1992-09-10 Nitrogen substituted acridine and cytochrome P450 inhibitors and methods of use
US08/100,917 US5466696A (en) 1992-09-10 1993-08-09 Tacrine and cytochrome P450 oxidase inhibitors and methods of use
PCT/US1993/008459 WO1994005296A2 (en) 1992-09-10 1993-09-08 Use of cytochrome p450 inhibitors for inhibiting the metabolism of nitrogen substituted acridine

Publications (1)

Publication Number Publication Date
DK0659082T3 true DK0659082T3 (da) 2002-06-17

Family

ID=26797688

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93923110T DK0659082T3 (da) 1992-09-10 1993-09-08 Anvendelse af cytochrom P450 inhibitorer til inhibering af metabolismen af nitrogensubstituerede acridiner

Country Status (18)

Country Link
US (1) US5466696A (da)
EP (1) EP0659082B1 (da)
JP (1) JPH08501105A (da)
KR (1) KR950703339A (da)
AT (1) ATE212845T1 (da)
AU (1) AU669586B2 (da)
CA (1) CA2141425A1 (da)
CZ (1) CZ48095A3 (da)
DE (1) DE69331546T2 (da)
DK (1) DK0659082T3 (da)
ES (1) ES2171419T3 (da)
FI (1) FI951024A (da)
HU (1) HU217845B (da)
NO (1) NO307955B1 (da)
NZ (1) NZ256940A (da)
PT (1) PT659082E (da)
SK (1) SK26495A3 (da)
WO (1) WO1994005296A2 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US5665386A (en) * 1995-06-07 1997-09-09 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
EP0831870A4 (en) * 1995-06-07 1998-09-16 Avmax Inc USE OF ESSENTIAL OILS TO INCREASE THE BIOAVAILABILITY OF ORAL PHARMACEUTICAL COMPOUNDS
US5716928A (en) * 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US6218383B1 (en) * 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
JP5143988B2 (ja) 1999-07-22 2013-02-13 オルガノジェネシス インク． 単離された肝細胞の機能を増強させるためのイン・ビボ誘導
AU2002367057B2 (en) * 2001-12-21 2007-01-11 Organogenesis Inc. Chamber with adjustable volume for cell culture and organ assist
AU2003270446A1 (en) * 2002-09-25 2004-04-19 The Board Of Trustees Of The University Of Illinois Method and composition for treating alzheimer's disease and dementias of vascular origin
US7583551B2 (en) 2004-03-10 2009-09-01 Micron Technology, Inc. Power management control and controlling memory refresh operations
DE102005044815A1 (de) * 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Verwendung von Inhibitoren des Na+/H+ Austauschers, Subtyp 5 (NHE5) zur Gedächtnisverbesserung
WO2008153722A1 (en) * 2007-05-22 2008-12-18 The Board Of Regents Of The University Of Texas System Post-translational regulation of catalytic activities of cytochrome p450 46a1 and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2233970A (en) * 1941-03-04 Quinoline compound and process of
DE1643240A1 (de) * 1966-09-16 1971-06-24 Boehringer Sohn Ingelheim Verfahren zur Herstellung neuer racemischer oder optisch aktiver 1-Phenoxy-2-aminoalkane
GB1338169A (en) * 1971-03-09 1973-11-21 Smith Kline French Lab Ureas thioureas and guanidines
SU429813A1 (ru) * 1971-08-20 1974-05-30 Способ лечения туберкулеза легких
AR223983A1 (es) * 1978-08-25 1981-10-15 Dainippon Pharmaceutical Co Un procedimiento para-preparar derivados de acido 6-halogeno-4-oxo-7-(1-piperazinil)-1,8-naftiridin-3-carboxilico
SU789112A1 (ru) * 1979-04-12 1980-12-23 Научно-исследовательский институт экспериментальной и клинической медицины Способ лечени экстрасистолической аритмии у детей
SU827081A1 (ru) * 1979-06-05 1981-05-07 Донецкий Медицинский Институт Им.M.Горького Способ лечени вазомоторных головныхбОлЕй
GB2091249A (en) * 1980-12-23 1982-07-28 Fordonal Sa Xanthine derivatives
SU1049065A1 (ru) * 1981-01-09 1983-10-23 Andronova Liliya Z Способ лечени заикани
JPS57134482A (en) * 1981-02-13 1982-08-19 Dainippon Pharmaceut Co Ltd 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8- naphthyridine-3-carboxylic acid-3/2 hydrate and its preparation
SU1156700A1 (ru) * 1982-01-19 1985-05-23 Научно-Исследовательский Институт Экспериментальной Медицины Амн Ссср Способ лечени неврозов
SU1210789A1 (ru) * 1983-07-21 1986-02-15 Военно-Медицинская Ордена Ленина Краснознаменная Академия Им.С.М.Кирова Способ диагностики функционального нарушени желудочной секреции
SU1196002A1 (ru) * 1984-06-28 1985-12-07 Запорожский государственный институт усовершенствования врачей им.М.Горького Способ лечени хронического сальпингоофорита
US4695573A (en) * 1984-10-25 1987-09-22 Hoechst-Roussel Pharmaceuticals Inc. 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds
US4835275A (en) * 1984-10-25 1989-05-30 Hoechst-Roussel Pharmaceuticals, Inc. Method of preparing 9-amino-1,2,3,4,-tetrahydroacridin-1-ones and related compounds
ATE63903T1 (de) * 1984-10-25 1991-06-15 Hoechst Roussel Pharma 9-amino-1,2,3,4-tetrahydroacridin-1-ol und verwandte verbindungen, verfahren zu ihrer herstellung und verwendung als arzneimittel.
US4754050A (en) * 1984-10-25 1988-06-28 Hoechst-Roussel Pharmaceuticals, Inc. 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds
US4631286A (en) * 1984-10-25 1986-12-23 Hoechst-Roussel Pharmaceuticals Inc. 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds
SU1537252A1 (ru) * 1985-03-28 1990-01-23 Научно-Исследовательский Институт Экспериментальной Медицины Амн Ссср Способ лечени парестезий полости рта
SU1416125A1 (ru) * 1986-02-21 1988-08-15 Одесский Научно-Исследовательский Институт Курортологии Способ лечени заболеваний суставов
SU1389050A1 (ru) * 1986-07-28 1990-08-30 Niiex Meditsiny An Sssr Cпocoб лeчehия aлkoгoлизma
US4816456A (en) * 1986-10-01 1989-03-28 Summers William K Administration of monoamine acridines in cholinergic neuronal deficit states
WO1989002739A1 (en) * 1987-10-05 1989-04-06 Pfizer Inc. 4-aminopyridine derivatives
US5019395A (en) * 1988-03-08 1991-05-28 Warner-Lambert Company Compositions with enhanced penetration
NZ231376A (en) * 1988-11-16 1992-05-26 Hoechst Roussel Pharma Hydroxy-1,2,3,4-tetrahydroaminoacridine derivatives, preparation and pharmaceutical compositions thereof
GB8827704D0 (en) * 1988-11-28 1988-12-29 Fujisawa Pharmaceutical Co New acridine derivatives & processes for their production
US4999430A (en) * 1989-07-31 1991-03-12 Warner-Lambert Company Derivatives of 1,2,3,4-tetrahydro-9-acrisinamine

Also Published As

Publication number Publication date
WO1994005296A3 (en) 1994-04-28
NZ256940A (en) 1996-03-26
US5466696A (en) 1995-11-14
HU9500704D0 (en) 1995-04-28
HUT70979A (en) 1995-11-28
DE69331546D1 (de) 2002-03-21
HU217845B (hu) 2000-04-28
NO307955B1 (no) 2000-06-26
KR950703339A (ko) 1995-09-20
AU669586B2 (en) 1996-06-13
PT659082E (pt) 2002-07-31
ATE212845T1 (de) 2002-02-15
WO1994005296A2 (en) 1994-03-17
DE69331546T2 (de) 2002-10-31
CZ48095A3 (en) 1995-12-13
AU5290593A (en) 1994-03-29
JPH08501105A (ja) 1996-02-06
NO950909L (no) 1995-03-09
CA2141425A1 (en) 1994-03-17
EP0659082B1 (en) 2002-02-06
SK26495A3 (en) 1996-05-08
NO950909D0 (no) 1995-03-09
FI951024A0 (fi) 1995-03-06
ES2171419T3 (es) 2002-09-16
FI951024A (fi) 1995-03-06
EP0659082A1 (en) 1995-06-28

Similar Documents

Publication Publication Date Title
ATE299890T1 (de) Inhibitoren von gamma-secretase
ATE93138T1 (de) Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie.
ATE150308T1 (de) Hemmung von thrombin
DK0755249T3 (da) Anvendelse af Maillard-reaktionsinhibitor til behandling af amyloidose-baseret sygdom
ATE165510T1 (de) Methode zur hemmung der proliferation weiche muskelzellen und der restenose
DE69532961D1 (de) Verwendung von porphyrine in der behandlung von multiple sklerose
DE69924641D1 (de) Behandlung von asthma anhand von mek-inhibitoren
DE69326776D1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n&#39;-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
DE69617469D1 (de) Behandlung von multipler sklerose
NO952309D0 (no) Anvendelse av riluzol ved behandling av Parkinsons sykdom og Parkinsonske syndromer
DK0659082T3 (da) Anvendelse af cytochrom P450 inhibitorer til inhibering af metabolismen af nitrogensubstituerede acridiner
NO965094D0 (no) [aÅ-annelerte pyrrolderivater og anvendelse av disse i farmasien
NO953370L (no) Anvendelse av riluzol ved behandling av neuro-AIDS
YU32196A (sh) Upotreba jedinjenja za pripremanje leka korisnog za inhibiranje migracije vaskularnih ćelija glatkog mišića
NO994330D0 (no) Metode for behandling av en tumor
UA27910C2 (uk) Засіб для підвищення експресії тромбомодуліну та підвищення активації протеїну с
DE69800859D1 (de) Verwendung von Moxonidin zur Behandlung neuropathischer Schmerzen
ATE190843T1 (de) Zubereitungen zur behandlung von impotenz, die ein alpha-1 inhibitor und ein alpha-2 inhibitor enthalten
PT986393E (pt) Utilizacao de um nitroxido ou de um seu pro-farmaco no tratamento profilactico e terapeutico do cancro
GEP20012511B (en) Method for Lowering Level of Lipoproteins (a) in Serum or Plasma of Mammals, Method for Treatment of Peripheral Vascular Diseases or Restenosis
MX9304626A (es) Derivados heterociclicos utiles en el tratamiento de enfermedades cardiovasculares.
DE69218200D1 (de) Behandlung von leberkrebs
LV11593A (lv) Dimetikona pielietojums aizcietejumu arstesana
ATE271867T1 (de) Behandlung der harninkontinenz und zusammenstellung dafür
RU94044487A (ru) Применение 2-фенил-3-ароилбензотиофенов для лечения мужского бесплодия